Eli Lilly and Company

As of June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt carries a market capitalization of 1.51T, placing it among publicly traded companies globally. Its enterprise value stands at 1.58T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Eli Lilly and Company Canadian Depositary Receipt's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt has 35.10B shares outstanding.

As of June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt trades at a trailing price-to-earnings ratio of 40.01. The price-to-sales ratio is 13.41, and the price-to-book ratio stands at 31.46.

As of June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt trades at an EV/EBITDA multiple of 31.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 13.95 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.05 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Eli Lilly and Company Canadian Depositary Receipt trades at an EV/FCF ratio of 81.13, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.58T versus a market cap of 1.51T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 162.07, indicating elevated leverage, while an interest coverage ratio of 198.95 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt posted a return on equity (ROE) of 102.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 34.73 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 36.53, useful for judging operating efficiency across full business cycles. The company generates approximately 2.30M in revenue per employee across its workforce of 49,250.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.95 indicates how many times Eli Lilly and Company Canadian Depositary Receipt sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt recorded 9.77B in income tax expense. That works out to an effective tax rate of 20.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 47.68B, leaving 37.91B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 42.41, while the 200-day moving average is 38.99.

Over the twelve months ended June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt generated 113.06B in revenue and converted that into 37.91B in net income, yielding earnings per share of 1.07. EBITDA reached 50.71B, while operating income came in at 56.21B.

As of June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt holds 12.70B in cash and equivalents against 77.93B in total debt, resulting in a net debt position of 65.22B. Total book value stands at 48.08B, with working capital of 24.03B providing operational flexibility.

Eli Lilly and Company Canadian Depositary Receipt produced 39.86B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -20.61B in capital expenditures, free cash flow totaled 19.24B - equivalent to 0.55 per share.

Over the twelve months ended June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt posted a gross margin of 83.40, reflecting its pricing power and cost economics. The operating margin of 49.72 and net profit margin of 33.53 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt paid dividends of 0.23 per share. The dividend payout ratio of 21.66 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.27, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.24, meaning Eli Lilly and Company Canadian Depositary Receipt raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Eli Lilly and Company Canadian Depositary Receipt has an Altman Z-Score of 8.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.